Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for ASHTON, LLC
-0.02 (-1.32%)
After Hours: 1.49 0.00 (0.00%)
Nov 27, 1:16PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.47 - 1.52
52 week 1.10 - 2.39
Open 1.48
Vol / Avg. 706,496.00/1.03M
Mkt cap 241.24M
P/E     -
Div/yield     -
EPS -0.24
Shares 161.91M
Beta 0.41
Inst. own 17%
Dec 8, 2015
Galena Biopharma Inc at Oppenheimer Healthcare Conference - 3:55PM EST - Add to calendar
Nov 9, 2015
Q3 2015 Galena Biopharma Inc Earnings Call - Webcast
Nov 9, 2015
Q3 2015 Galena Biopharma Inc Earnings Release
Nov 3, 2015
Galena Biopharma Inc at �EBD BIO Europe- Fall
Sep 10, 2015
Galena Biopharma Inc at BioCentury NewsMakers in the Biotech Industry Conference
Sep 9, 2015
Galena Biopharma Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -392.81%
Operating margin - -558.56%
EBITD margin - -550.84%
Return on average assets -27.60% -43.46%
Return on average equity -62.31% -170.48%
Employees 57 -
CDP Score - -


4640 SW Macadam Ave Ste 270
PORTLAND, OR 97239-4232
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Galena Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Its development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including cancer immunotherapy programs led by NeuVax (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase III clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancer and in a Phase 1b given sequentially with GALE-302.

Officers and directors

Sanford J. Hillsberg J.D. Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer, Independent Director
Age: 58
Bio & Compensation  - Reuters
Ryan M. Dunlap CPA Chief Financial Officer, Vice President, Secretary
Age: 45
Bio & Compensation  - Reuters
Bijan Nejadnik M.D. Executive Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Joseph Lasaga Vice President - Business Development
Bio & Compensation  - Reuters
Thomas J. Knapp Interim General Counsel
Age: 62
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Irving M. Einhorn Independent Director
Age: 72
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters